Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.,Jan. 8, 2025/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website atwww.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.
Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232ir@rigel.com
Media:David RosenArgot Partners646.461.6387david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345248.html
SOURCE Rigel Pharmaceuticals, Inc.
Released January 8, 2025